UCSF Search Toolbar
UCSF Radiation Oncology

Residency Program

PGY5: Holman pathway

Inspiration: My Parents

Area of interest: Neuro-Oncology

Gautam Prasad, MD, PhD

Educational Background

Radiation Oncology Residency (Holman Pathway), University of California San Francisco (2007-2011)

Preliminary Internal Medicine Internship, University of Alabama School of Medicine (2006-2007)

M.D., University of Alabama School of Medicine (2006)

Ph.D., Pharmacology & Toxicology, University of Alabama School of Medicine (2004)

B.S. Biology, The College of New Jersey (1998) 

Resident Awards

2010 Roentgen Resident/Fellow Research Award

University of California San Francisco – Clinical and Translational Science Institute (CTSI) Resident Grant “Sensitization of glioblastoma to adjuvant erlotinib using a combined  P13K/mTOR inhibitor”

51st ASTRO Annual Meeting Basic Science Travel Award

Current Research

Rational targeting of the phosphatidylinositol 3-kinase pathway in glioblastoma and identification of susceptible genotypes

The poor prognosis of gliomas has not changed significantly over the last several decades despite aggressive research and therapies.  More recent efforts have attempted to take advantage of the unique, yet heterogeneous molecular milieu of these tumors to generate novel therapeutics.  However, no agent has yet shown clear cut clinical benefit.  Our study utilizes a series of three small molecules that specifically inhibit Class I PI3K (XL147), PI3K/mTOR (XL765) and Akt/S6K (XL418).  Using these agents, we will examine the changes to the downstream cascade that results from inhibition of these specific enzymes.  Furthermore, we will examine their interaction with conventional- (radiation, temozolomide [TMZ]) and biologic-based (EGFR inhibitors) therapies in both in vitro and in vivo models.  For our studies we will use genetically well-characterized GBM cells serially passaged in nude mice, that are known to maintain their parental genotypes better than cells grown exclusively in culture.  These experiments are meant to provide a solid mechanistic and pharmacodynamic foundation upon which clinical trials may be based. 

Selected Resident Publications/Presentations

Prasad G, Haas-Kogan DA.  Radiation induced gliomas. Expert Rev Neurother, 9(10):1511-7, 2009.
Haas-Kogan D, Prasad G, Mueller S, Yang X, DuBois S, Sottero T, Polley M, James D, Berger M, Prados M, Aftab D, Matthay K. Rational incorporation of novel agents into multimodality treatment of glioma and neuroblastoma.  American Association for Cancer Research (AACR) Annual Meeting, Washington DC, April, 2010.
Mueller S, Yang X, Sottero T, Prasad G , Polley, MY, Matthay K, Dubois S, Weiss, W, Haas-Kogan D.  Suberoylanilide hydroxamic acid (SAHA) and Radiation for the Treatment of metastatic Neuroblastoma.  Cancer Lett. 2011, in press.
Prasad G, Sottero T, Yang X, Mueller S, James CD, Polley MY, Berger M, Aftab DT, Prados MD, Haas-Kogan D.  Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide, Neuro Oncol. Advance Access published February 11, 2011, doi:10.1093/neuonc/noq193.
Prasad G, Chennupati S, McDermott MW, Sneed PK.  Outcomes following radiosurgery for the treatment of primary or metastatic intracranial sarcomas.  Manuscript in preparation.

Other Publications/Presentations

Wang Z, Wang H, Rhie JK, Covey JM, Liang P, Wang S, Wang C, Hu Y, Prasad G, Nan L, Hill DL, Zhang R. Determination of desoxyepothilone B in nude mice plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.  J Pharm Biomed Anal., 42(2):272-6, 2006.

Prasad G.  Inhibition of MDM2 oncogene expression as a novel approach to the treatment of glioblastoma multiforme.  Doctoral dissertation, University of Alabama, Birmingham, 2004.

Prasad G, Wang H, Hill D, Zhang R.  Recent advances in experimental molecular therapeutics for malignant gliomas.  Curr Med Chem Anti-Canc Agents., 4(4):347-361, 2004.

Zhang Z*, Wang H*, Prasad G*, Mao L, Yu D, Bonner JA, Agrawal S, and Zhang R. Radiosensitization by antisense-MDM2 mixed backbone oligonucleotides in in vitro and in vivo human cancer models.  Clin Cancer Res., 10(4):1263-1273, 2004. *Indicates co-first author.

Prasad G, Wang H, Agrawal S, and Zhang R.  Antisense oligonucleotides targeted to MDM2 oncogene as a novel approach to the treatment of glioblastoma multiforme.  Anticancer Res., 22(1):107-116, 2002.

Wang H, Prasad G, Buolamwini JK, and Zhang R.  Antisense anticancer oligonucleotide therapeutics.  Curr Cancer Drug Targets, 1:177-196, 2001.

Back to Top